Cost-effectiveness of HIV post-exposure prophylaxis in France

AIDS

Volumn 20, Issue 13, 2006, Pages 1753-1761

  Herida, Magid ^a   Larsen, Christine ^a   Lot, Florence ^a   Laporte, Anne ^b   Desenclos, Jean Claude ^a   Hamers, Françoise F ^a  

^a INSTITUT DE VEILLE SANITAIRE   (France)

^b Samu Social de Paris   (France)

Author keywords

Cost effectiveness; France; HIV; Post exposure prophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DRUG COST; FOLLOW UP; HEALTH PROGRAM; HEALTH SURVEY; HETEROSEXUALITY; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; OCCUPATIONAL EXPOSURE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SEXUAL INTERCOURSE; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; FEMALE; FRANCE; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; QUALITY-ADJUSTED LIFE YEARS; SUBSTANCE ABUSE, INTRAVENOUS; UNSAFE SEX;

EID: 33748043952     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000242822.74624.5f     Document Type: Article

References (53)

1. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-1180.
2. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997; 337:1485-1490.
3. Bottiger D, Johansson NG, Samuelsson B, Zhang H, Putkonen P, Vrang L, et al. Prevention of simian immunodeficiency virus SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS 1997; 11:157-162.
4. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 1995; 270:1197-1199.
5. Lamontagne F, Pillonel J, Laporte A. Post-exposure prophylaxis after non-occupational HIV exposure: hospital-based physicians' experiences and attitudes [in French]. Bull Epidémiol Hebdomadaire 1998; 42:183-185.
6. Ministère de la Santé Publique et de l'Assurance Maladie. Measures against human immunodeficiency virus transmission among health workers and recommended procedures after exposure to blood or other biologic fluid [in French]. Paris: Ministère de la Santé Publique et de l'Assurance Maladie. 1995; vol. 81, pp. 1-11.
7. Ministère de l'Emploi et de la Solidarité. Post-exposure HIV prophylaxis: recommendations for implementing an antiretroviral therapy after exposure to HIV [in French]. Paris: Ministère de l'Emploi et de la Solidarité. 1998; vol. 228, pp. 1-2.
8. Laporte A, Jourdan N, Bouvet E, Lamontagne F, Pillonel J, Desenclos JC. Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physician's experiences and attitudes. AIDS 2002; 16:397-405.
9. Rey D, Bendiane MK, Moatti JP, Wellings K, Danziger R, MacDowall W, and the European Study Group on HIV Testing Policies and Practices in Europe. Post-exposure prophylaxis after occupational and non-occupational exposures to HIV: an overview of the policies implemented in 27 European countries. AIDS Care 2000; 12:695-701.
10. Centers for Diseases Control and Prevention. Management of possible sexual, injecting drug use, or other non occupational exposure to HIV, including considerations related to antiretroviral therapy. MMWR Morb Mortal Wkly Rep 1998; 47 (RR-17):1-14.
11. Centers for Disease Control and Prevention. Antiretroviral exposure prophylaxis after sexual, injection drug use, or other non occupational exposures to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Morb Mortal Wkly Rep 2005; 54 (RR-2):1-20.
12. Lurie P, Miller S, Hecht F, Chesney M, Lo B. Postexposure prophylaxis after nonoccupational HIV exposure: clinical, ethical and policy considerations. JAMA 1998; 280:1769-1673.
13. Pinkerton SD, Holtgrave DR, Kahn JG. Is post-exposure prophylaxis affordable? AIDS 2000; 14:325.
14. Low-Beer S, Weber AE, Bartholomew K, Landolt M, Ouram D, Montaner JSG, et al. A reality check: the cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk. AIDS 2000; 14:325-326.
15. Merchant R. Post-exposure prophylaxis affordability: a clearer reality. AIDS 2001; 15:541-542.
16. Braitstein P, Chan K, Beardsell A, McLeod A, Montaner JSG, O'Shaughnessy MV, Hogg RS. Another reality check: the direct costs of providing post-exposure prophylaxis in a population-based programme. AIDS 2001; 15:2345-2347.
17. Pinkerton SD, Holtgrave DR, Pinkerton HJ. Cost effectiveness of chemoprophylaxis after occupational exposure to HIV. Arch Intern Med 1997; 157:1972-1980.
18. Pinkerton SD, Holtgrave DR, Bloom FR. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV. AIDS 1998; 12:1067-1078.
19. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS 2004; 18:2065-2073.
20. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of post exposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med 2004; 164:46-54.
21. Rothenberg RB, Scarlett M, Del Rio C, Reznik D, O'Daniels C. Oral transmission of HIV. AIDS 1998; 12:2095-2105.
22. Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr 1992; 5:1116-1118.
23. Henderson DK, Fahey BJ, Willy M, Schmitt JM, Carey K, Koziol DE, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation. Ann Intern Med 1990; 113:740-746.
24. Centers for Diseases Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for post exposure prophylaxis. MMWR Morb Mortal Wkly Rep 2002; 50:1-42.
25. Bochow M, Jauffret-Roustide M, Michel A, Schiltz M. Evolution of sexual behaviours and lifestyles. Results of surveys performed in gay men press 1985-2000 [in French]. In: Homosexualité au temps du sida. Paris: Agence Nationale de Recherche sur le Sida; 2003. pp. 35-54.
26. Observatoire Français des Drogues et des Toxicomanies. Transversal approaches on illicit drugs [in French]. In: Drugs and addiction. Indicators and trends 2002. Paris: Ministère de l'Emploi et de la Solidarité; 2002. pp. 44-46.
27. Gouëzel P. Free and anonymous HIV testing activity in France. [in French]. Bull Epidémiol Hebdomadaire 2002; 43:213-217.
28. Anonymous. Vidal dictionary [in French]. Paris: Editions du Vidal; 2002.
29. Anonymous. Biologic acts nomenclature [in French]. Paris: Union des Caisses Nationales de Sécurité Sociale; 2002.
30. Longini IM, Clark WS, Karon JM. Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population-based cohort. Am J Epidemiol 1993; 137:1229-1239.
31. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997; 315:1194-1199.
32. Anonymous. Antiretroviral therapy. In: Management of HIV-infected persons. Recommendations from an experts' group led by Pr Delfraissy [in French]. Paris: Flammarion Médecine-Sciences; 1999. pp. 29-44.
33. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:54-62.
34. Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther 2002; 7:257-266.
35. Ministère de l'Economie, des Finances et de l'Industrie. Economic and social report annexed to the draft Law of Ministry of Finances, 2005 [in French]. Paris: Ministère de l'Economie, des Finances et de l'Industrie; 2004.
36. Pinkerton SD, Holtgrave DR. A method for evaluating the economic efficiency of HIV behavioural risk reduction interventions. AIDS Behav 1998; 2:189-201.
37. Yazdanpanah Y, Goldie SJ, Paltiel AD, Losina E, Coudeville L, Weinstein MC, et al. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. Clin Infect Dis 2003; 36:86-96.
38. Arveux P, Wait S, Schaffer P. Building a model to determine the cost-effectiveness of breast cancer screening in France. Eur J Cancer Care 2003; 12:143-153.
39. Hanslik T, Boëlle PY, Schwarzinger M, Carrat F, Freedberg KA, Valleron AJ, et al. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine 2003; 21:3614-3622.
40. Roland ME, Martin JN, Grant RM, Hellmann NS, Bamberger JD, Katz MH, et al. Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure. J Infect Dis 2001; 184:1608-1612.
41. Greub S, Gallant S, Zurn P, Vannotti M, Bürgisser P, Francioli P, et al. Spare non-occupational HIV post-exposure prophylaxis by active contacting and testing of the source person. AIDS 2002; 16:1171-1176.
42. Laufer FN. Cost-effectiveness of syringe exchange as an HIV prevention strategy. J Acquir Immune Defic Syndr 2001; 28:273-278.
43. Emmanuelli J, Jauffret-Roustide M. Multicentre and multisite study on frequency and determinants of HIV and HCV transmission risk among drugs users [in French]. Saint-Maurice, France: Institut de Veille Sanitaire; 2003.
44. Jauffret-Roustide M. Public Health policies evolution. In: Drugs: social, economic and political approach [in French]. Paris: Etudes de la Documentation Française; 2005. pp. 111-142.
45. Debab Y, Farthouk C, Abboud P, Gueit I, Borsa-Lebas F, Caron F. HIV post-exposure prophylaxis: influence of the mode of exposure on the compliance and tolerance of procedure. In: XIIIth International AIDS Conference. Durban, 2000 [Abstract ThPpC1448].
46. Fleury D, Che D, Rosenheim M, Astagneau P, Brucker G. HIV post-exposure prophylaxis in Paris area hospitals: analysis of 3354 treatment demands [in French]. Bull Epidémiol Hebdomadaire 2001; 11:45-46.
47. Martin JN, Roland ME, Neilands TB, Krone MR, Bamberger JD, Kohn RP, et al. Use of post exposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004; 18:787-792.
48. Lot F, Larsen C, Basselier B, Laporte A. Evolution of HIV post-exposure prophylaxis in France. July 1999-December 2002 [in French]. Bull Epidémiol Hebdomadaire 2002; 36:173-175.
49. Larsen C, Lot F, Basselier B, Herida M, Semaille C. HIV post exposure prophylaxis prescriptions in France. In: XVth International AIDS Conference. Bangkok, 2004 [Abstract TuPeB4649].
50. Rabaud R, Bevilacqua S, Beguinot I, Dorvaux V, Schumacher H, May T, et al. Tolerability of post exposure prophylaxis with zidovudine, lamivudine and nelfinavir for human immunodeficiency virus infection. Clin Infect Dis 2001; 32:1494-1495.
51. Parkin JM, Murphy M, Anderson J, El-Gadi S, Forster G, Pinching AJ. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet 2004; 355:722-723.
52. Hudgens MG, Logini IM, Vanichseni S, Hu DJ, Kitayaporn D, Mock P, et al. Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drugs users in Bangkok, Thailand. Am J Epidemiol 2002; 155:159-168.
53. Desenclos JC, Costagliola D, Commenges D, Lellouch J. HIV prevalence in France [In French]. Bull Epidemiol Hebdomadaire 2005; 11:41-44.